HIGHLIGHTS
- What: The analysis reveals that biosimilar drugs have significant cost-effectiveness improved patient affordability and ease of clinical use in diabetic glycemic control. The aim of this study was to investigate the clinical advantages of biosimilars in diabetic glycemic control compared to conventional insulin therapy, and to analyze the advantages, challenges, and coping strategies of biosimilars by means of a review.
- Who: Yifei Wang from the Westfield Secondary School, Toronto, ON M B , Canada have published the research: Advantages of biological analogues in blood glucose control of diabetes from a clinical perspective, in the : Proceedings . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.